Interim Data for Merck’s MK-3475, an Investigational Anti-PD-1 Immunotherapy … – DailyFinance

by lowes1 on October 2, 2013

Interim Data for Merck's MK-3475, an Investigational Anti-PD-1 Immunotherapy
DailyFinance
"These early data in lung cancer patients were the basis for Merck's decision to rapidly advance MK-3475 into a Phase II/III clinical trial in NSCLC," said Dr. Eric H. Rubin, vice president, Oncology, Merck Research Laboratories. "We look forward to
Merck's Immune System-Based Cancer Drug Works in 1 in 4Bloomberg

all 6 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: